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Hematopoietic Growth Factors: Understanding Functional Diversity 
in Structural Terms 
By Kenneth Kaushansky and P. Andrew Karplus 
HE  HEMATOPOIETIC growth factors are a diverse  T  group of acidic  glycoproteins  responsible for the devel- 
opment,  maintenance,  and  functional activation of im- 
mune surveillance and effector cells.’”  At recent count, at 
least  1 5 ligand-receptor systems had been  physiologically 
characterized, biochemically purified, and cloned. The in- 
teraction between a hematopoietic growth factor and its re- 
ceptor is both avid and specific. Typical dissociation con- 
stants for high affinity binding approximate 10 pmol/L; the 
receptor-ligand interaction is absolutely specific, although a 
few notable exceptions have recently been described. In ad- 
dition, several of these cytokines exist in both soluble and 
membrane-bound   form^.^,^  Most are  monomeric but  at 
least three are  And several of the soluble proteins 
interact with components ofthe extracellular  matrix to con- 
tribute to progenitor and effector cell function.’ Despite this 
complexity, detailed study of the growth factors themselves 
has shown a remarkable conservation of form and function; 
indications are that  virtually all of these growth factors 
adopt a four-helix bundle tertiary fold, and that two distinct 
helical faces of the proteins, which display prominent struc- 
tural conservation amongst the family, are responsible for 
receptor engagement. 
Much has been written about the hematopoietic growth 
factors over the past 5 years. An on-line medical literature 
search revealed over 25 entries during this period relating to 
structural or functional aspects of just one member of this 
group, granulocyte-macrophage colony-stimulating factor 
(GM-CSF). Most studies attempt to contribute to funda- 
mental questions of biochemistry and physiology. Do func- 
tional similarities amongst the growth factors imply struc- 
tural  homology?  What  forces  govern  protein-protein 
(receptor-ligand) interactions? What  primary  interactive 
events between growth factors and receptor trigger signal 
transduction? Many experimental approaches to these is- 
sues are now available and have contributed to many basic 
concepts of growth  factor biology.  However, additional 
questions arise. Are the methods applied to structure-func- 
tion analysis valid? Do functional studies add to our under- 
standing once physical methods have elucidated tertiary or 
quaternary  structures? Are  the two primary methods of 
structure determination (crystallography  and magnetic reso- 
nance spectroscopy)  competitive or complementary? Once 
a critical mass of data has accrued, can this information be 
used to predict the structures of related cytokines, or to engi- 
neer “muteins?’ 
In general, sites of protein-protein interaction typically 
involve 10 or more residues on each side and amount to 
-20%  ofthe surface area (7 to 10 nmz  lo) of a typical growth 
factor. A detailed dissection of the interactive events be- 
tween  ligand and receptor is essential for a better under- 
standing of the effects of different cytokines on hematopoie- 
sis. A previous review”  details the  interaction  from the 
receptor side ofthe equation. The focus ofthis review will be 
to critically evaluate the methodologies applied and high- 
light the progress made studying structure-function aspects 
of this family of cytokines. In so doing we  hope to clarify 
some of the molecular insights gained into how functional 
diversity may arise from a shared structural motif. For the 
purposes of this review, we will focus on seven of the cyto- 
kines (interleukin-2 [IL-21, IL-3, IL-4, IL-5, GM-CSF, M- 
CSF,  and growth hormone [GH]) for which the greatest 
structural and functional data are available. Hopefully, a 
better understanding of the common and distinct features of 
these proteins will provide a framework for detailed study 
and for beneficial therapeutic manipulation of multiple cy- 
tokine-receptor interactions. 
FUNCTIONAL  DIVERSITY  OF  CYTOKINES 
Hematopoietic growth factors support a wide  array of 
physiologic  functions. For example,  in conjunction with spe- 
cific antigen presented in the context ofthe major histocom- 
patibility complex, IL2  contributes to B- and T-cell prolifer- 
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ation,” and in conjunction with IL- 1 the cytokine promotes 
natural killer (NK) cell production from marrow progeni- 
tor~.’~  IL-2 acts together with interferon (1FN)-a to promote 
the maturation of B cells,L4  and it acts directly to stimulate 
macrophage and NK cell production of IFN-y " and to aug- 
ment macrophage cytotoxicity.’6  In contrast, GM-CSF, in 
conjunction with G-CSF, IL-5, and M-CSF, respectively, 
supports the proliferation and differentiation of neutrophil, 
eosinophil, and monocyte precursors, and directly stimu- 
lates their  mature progeny to become functionally acti- 
~ated.”-’~  Furthermore, GM-CSF acts to promote differen- 
tiation and survival of  peripheral blood dendritic cells,2o 
augments the  primary  antibody  response by  enhancing 
function of antigen-presenting cells,’’  activates endothelial 
cells to proliferate and migrate,” and together with erythro- 
poietin (Epo) directly stimulates the proliferation and dif- 
ferentiation of intermediate and late erythroid progenitor 
cells.23  On a superficial level, these cytokines would appear 
to share little target cell specificity  or functional activity. Yet 
a number of recent studies using growth factor-dependent 
cell lines engineered to express alternate or chimeric cyto- 
kine receptors indicate that physiologic responsiveness is 
dependent only on the context of the extracellular domain 
of the transduced re~eptor.’~  For example, human GM-CSF 
stimulates murine IL-3-dependent cells to proliferate if the 
cells are first transduced with a chimeric human GM-CSF/ 
murine Epo receptor.25  IL-2-dependent  cells can also be 
made to proliferate in response to GM-CSF if first trans- 
duced with the high-affinity GM-CSF receptor.26  Further- 
more, the phosphoprotein signaling pattern of chimeric re- 
ceptors is also primarily dependent on the specificity of the 
extracellular domain.”  These studies suggest that most, if 
not all, of these growth factors signal through fundamen- 
tally similar mechanisms and via  overlapping pathways. 
The appearance of a number of shared phosphoproteins in 
response to stimulation by diverse cytokines has reinforced 
this ~oncept~”~~  and implies that biologic responses are dic- 
tated primarily by the patterns of receptor display. Put more 
simply, hematopoietic specificity of  action is dependent 
only on the specifics of the ligand-receptor interaction and 
on the cellular distribution of cytokine receptors. 
STRUCTURAL  ANALYSIS: METHODS OF  STUDY 
The ability to gain detailed insights into the structure- 
function relationships of hematopoietic growth factors de- 
pends  on  the  availability of  accurate three-dimensional 
models. Currently there are two experimental methods for 
defining such structures: single crystal x-ray diffraction (crys- 
tall~graphy;~~.”)  and  multidimensional nuclear magnetic 
resonance spectroscopy (NMR;45946).  Together, these meth- 
ods have been used over the past few years to determine the 
structures of many hematopoietic cytokines (Table 1). The 
x-ray-  and NMR-based  methods have in common the re- 
quirement for large amounts  of pure protein (typically 10 to 
100 mg), so that cloning and overexpression technologies 
have constituted crucial components of recent structure de- 
terminations. Because these two approaches toward struc- 
tural  study have different advantages and disadvantages, 
and they use very different types of information to define a 
Table 1. Structural Information on the Human Hematopoietic 
Growth Factors and Growth Hormone 
Resolution or 
Growth  Constraints/  R-Factor 
Factor  Method  Site (nm)  or RMSD  PDB Code  Reference 
GM-CSF  X-ray  .24  20%  1  GMF  30 
X-ray  .28  25%  1  RGM  31 
IL-2  X-ray  .25  20%  31NK  32, 33 
IL-4  NMR  .83  0.1 nm  1BBN  34 
NMR  1.41  0.1 nm  1lTL  35 
X-ray  ,225  22%  1  RCB  36 
X-ray  ,235  23%  37 
M-CSF  X-ray  .25  20%  38 
11-5  X-ray  .24  21%  39 
G-CSF  X-ray  .30  22%  1  RHG  40 
GH/GHR  X-ray  .28  20%  2HHR  41 
complex 
For x-ray  structures, resolution and R-factor are reported, which is 
near or  below 20% for  well-refined structures. For structures derived 
from NMR methods, the number of constraints  per residue and the level 
of precision of main chain atoms in the protein structure  (RMSD)  is given. 
For a well-refined x-ray structure, the equivalent number is roughly reso- 
lution/8. The PDB entry code used for obtaining the coordinates from 
the Brookhaven protein data bank4* is also given for those coordinates 
that have been deposited. 
structure, they are in many ways complementary (eg, ref 
47). 
The crystallographic  approach to structure determination 
begins with the growth of single crystals that are able to 
diffract x-rays.  This is the most uncertain step in protein 
crystallography, because every protein has unique crystalli- 
zation properties and crystallization requires a trial and 
error search of many   variable^.^*^^^  Once crystals are ob- 
tained, it is a simple matter to determine their diffraction 
limit, which is a reliable indicator of how much structural 
detail will be  available when the structure is solved. The 
initial determination of the structure is often very easy if the 
structure of a close homolog is known. However, if no suffi- 
ciently similar structure is available then the isomorphous 
replacement technique, which usually takes a few months to 
a few years, must be used. All of the crystal structures listed 
in Table  1 were solved by  the isomorphous replacement 
method, but with the growing database of known structures, 
many future growth factor structures may be solved by mo- 
lecular replacement. 
The crystallographic  result is an electron density map that 
gives an image of the protein structure as a whole. Using the 
sequence of the protein, a model is built that matches the 
image in the electron density map. Because the experimen- 
tal image of the protein is imperfect, the model building 
process can be quite difficult and errors can result,” such as 
were initially made for IL-2.5L  The holistic nature of the 
crystallographic result is such that if errors are made, the 
overall shape and secondary structures of the molecule will 
be positioned correctly in space, but some portions of the 
structure may be modeled with the incorrect parts of the 
amino acid sequence.  Refinement ofthe  structure will gener- 
ally allow major errors to be corrected, but at medium reso- 
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lution (near 0.3 nm) details of conformation may still not be 
accurate. It must always be remembered that crystallogra- 
phy results in the coordinates of a single conformation of 
the protein  as seen  in the particular crystal form under 
study. Although experience suggests that the overall fold of 
a structure is not altered by crystallization, protein mole- 
cules are dynamic5’ and most residues, in particular those 
on the surface that may be important for receptor recogni- 
tion, are free to adopt many conformations. 
Protein structure determination by  NMR has no major 
uncertainties that compare with crystallization, but does 
have some other limitations: proteins must be smaller than 
-40  kD and soluble at concentrations  near 1 mmol/L with- 
out aggregating. Also, for efficient determination of struc- 
tures larger than -  10 kD, it is important that isotopically 
enriched (I3C  and I5N) samples of the protein can be pro- 
duced. Most hematopoietic cytokines meet the molecular 
weight requirement and can be expressed in bacterial sys- 
tems where isotopic labeling is not a problem. However, 
because not all meet the solubility requirement,  the suitabil- 
ity of a given protein for structural analysis is best evaluated 
by  the simple collection of an NMR spectrum. The next 
step is to use two-, three-, and four-dimensional NMR ex- 
periments to assign each resonance to a unique atom in the 
structure. During the assignment process,  information is 
gained about the local conformation of each residue, so that 
the secondary structure can be assigned. Key information 
for  defining the  secondary and  tertiary  structure comes 
from the so-called NOE (Nuclear Overhauser Effect) signals 
which can be seen between resonating atoms in the struc- 
ture that are within -0.5  nm of one another. To define the 
tertiary structure of a protein, all observed NOE peaks are 
tabulated to give a set of  distance constraints, and these 
distance constraints are used to create many possible struc- 
tures that are compatible with the measurements. The multi- 
ple structures are often averaged (and subjected to energy 
minimization) to yield a single final structure, and the qual- 
ity of the structure is usually measured by  assessing how 
much the individual structures deviate from the average 
structure. Clearly, the more distance constraints that are 
used, the better defined the structure should be. 
This highlights one of the key differences between NMR 
and crystallography: While crystallography delivers a com- 
plete image of the protein that must be interpreted in terms 
of  local  structures,  NMR  delivers  many  individual re- 
straints that must be combined to build up the complete 
structure from its parts. Thus, while a medium resolution 
crystallographic structure may have lower average coordi- 
nate errors than an NMR-determined structure, the NMR 
structure will often define local structures more accurately. 
When individual protein structures, such as IL-4 (Table l), 
have been determined by both crystallography and NMR, 
the agreement between the structures  is quite good, showing 
that both methods are able to provide a solid foundation for 
structure-function  studies. 
STRUCTURAL SIMILARITIES OF  CYTOKINES 
The general details of IL-2 structure were first established 
by Brandhuber et al” in 1987. Using a low-resolution elec- 
tron density map determined by x-ray crystallography  these 
investigators proposed that IL-2 assumed an antiparallel al- 
pha helical bundle. Although details of the connectivity of 
the initial structure were incorrect (based on theoretical ar- 
gument~,~~  NMR  data,53 and  refined  crystallography 
data33),  the four-helix bundle topology has served as the 
benchmark structure for subsequent cytokine analyses. Al- 
most coincident with publication of the IL-2 structure, the 
tertiary fold of an engineered porcine GH was e~tablished.~~ 
Although not a member of the (functionally  defined) hema- 
topoietic family of proteins, the GH receptor is a member of 
the (structurally defined) family of hematopoietic growth 
factor receptors55  (and see below), suggesting that GH may 
share structural features with other cytokines. Key elements 
of the porcine GH fold are similar to the refined structure of 
IL-2 including a four-helix bundle, long cross-over loops 
between the first two and the last two helices, up-up-down- 
down helix orientation, and a proline-induced break in the 
second helix. Subsequent solution of the structure for other 
hematopoietic cytokines has  reinforced this concept. As 
shown in Figs 1 and 2, the tertiary structures of GM-CSFM 
and IL-436,37  are remarkably similar to each other (and to 
those of IL-2, G-CSF, IL-5, and GH). Especially remarkable 
is that although the M-CSF receptor, c-fms, is a member of 
an otherwise distinct family of membrane-bound tyrosine 
kinases, the core structural topology of the M-CSF mono- 
mer is nearly identical to that of GM-CSF and GH.38  To- 
gether, the folds of these seven cytokines thus serve as a 
useful database to generate several general principles of he- 
matopoietic growth factor structure. First, these cytokines 
assume a left-handed four-helix bundle. Second, long over- 
hand loops, which often contain short secondary structures, 
connect the first two and last two helices. For example, two 
/3  sheets have been described in the folds for GM-CSF, M- 
CSF, IL-4, IL-5, and IL-2.30,3z*37-39  Third, packing and helix 
orientation (up-up-down-down) is remarkably similar, as 
judged by minimal deviation upon superimposition of the 
GM-CSF, IL-4, M-CSF, and GH core folds37,38  (and Fig 2). 
Furthermore, although helix  length varies amongst these 
proteins, pairwise analysis illustrates that a minimal core of 
-60  residues is spatially conserved; helix length variation is 
accounted for by  extension above the core fold (Fig 2). 
Fourth, the helices relate to one another such that the first 
and fourth helices are antiparallel  and adjacent, and the first 
and third helices are antiparallel and adjacent (see Fig  1). 
And fifth, many, if not most, of the helices are amphipathic, 
presenting a hydrophobic face responsible for helix-helix 
packing stability and a hydrophilic face free to interact with 
the environment (receptors). 
As  noted, helix length varies amongst these proteins. F. 
Bazan has proposed dividing the four-helix bundle cyto- 
kines into long- and short-helix subfamilies (personal com- 
munication, January 1993). On the basis of their crystalline 
structure, the former includes GH and G-CSF, the latter, 
IL-2, GM-CSF, IL-4, IG5, and M-CSF. The extra 5 to 10 
residues in each helix of the longer helix subfamily extend 
above the region of  maximal alignment with short-helix 
subfamily members, as can be  seen for the GH helices 
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IL4  GMCSF 
shown in Figs 3, 4, and 5. However, the functional conse- 
quences of these structural differences  are not clear. 
The recent cloning and sequence analysis of a large num- 
ber of hematopoietic  growth factor receptors  has also shown 
a highly conserved core of primary amino acid ~imilarity~~*~~ 
including a distinct pattern of two  disulfide bonds and a 
WSXWS “hinge” region. Furthermore, several cytokine re- 
ceptors share additional regions of sequence 
some of which are important for receptor functi~n.~’  Given 
the presumed structural similarities  amongst different  hema- 
topoietic growth factor receptors and their signaling  mecha- 
nisms (vide supra), perhaps it is not surprising that the cyto- 
kines themselves also share structural features. 
The recent solution of the structure of a cocrystal of GH 
and its receptoP may shed additional insights into the in- 
teraction between  the hematopoietic growth  factors and 
their receptors. Two GH receptor molecules simultaneously 
Fig 2.  A superimposition of 
the smoothed a-C backbones  of 
GM-CSF (green), IL-4  (red), and 
M-CSF (yellow) is shown as a 
stereo diagram. The orientation 
is similar to that shown  in  Fig 1. 
The figure was generated using 
the software Insight from Bio- 
sym,  Inc (San Diego, CA). 
1 
%. 
N 
MCSF 
Fig  1.  The  three-dimen- 
sional structures of  11-4  (left), 
GM-CSF, (middle),  and M-CSF 
(right). Ribbon diagrams of the 
three cytokines  are  displayed 
highlighting the conserved ele- 
ments of the four-helix bundle 
(spirals), short  stretches of 6 
sheet (arrows) connecting the 
first two and second two he- 
lices  and  up-up-down-down 
helix orientation.  The amino (N) 
and carboxyl (C) termini are in- 
dicated. 
contact distinct sites of the monomeric hormone. Of further 
interest, the majority of sites of GH/GH receptor interac- 
tion reside in the helical core conserved among the cyto- 
kines of known structure. However, in contrast to the GH 
system, most of the hematopoietic growth factor receptors 
are heterodimeric making the relevance of direct applica- 
tion of this model ~ncertain.’~  In the absence of experimen- 
tally determined structures of other hematopoietic growth 
factor/receptor  interactions, structure-function  studies  have 
been  undertaken. A large body of data has now accumu- 
lated allowing the formulation and testing of models of cy- 
tokinejreceptor interaction. 
STRUCTURE-FUNCTION ANALYSIS:  METHODS OF  STUDY 
A  hematopoietic growth  factor can  be  conveniently 
viewed as a structural scaffold on which sits critical side 
chains of proper charge density, hydrogen bonding poten- 
L 
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From STRUCTURE-FUNCTION OF  HEMATOPOIETIC CYTOKINES  3233 
GH  IL-2  GM  I L-4  I L-3  I  L-5 
Fig 3.  Cylindrical plots of helix A from several members of the hematopoietic growth factor family. The alignment  of the helices of GH. 
IL-2, GM-CSF, IL-4, and 11-5 were taken from a pairwise superimposition of the four core helices of the cytokines as determined  by x-ray 
crystallography. A multi-sequence  alignment  was performed  for the proposed  helices  of 11-3. The residues in  outlined  font have been shown 
to be important for biologic activity (X‘ ,  10%  to 100%  activity; X2, <  10%  activity; X’,  antagonist; X4, superagonist) or to directly contact 
receptor (X”). The data for 11-2 were derived  from mutational  analysisof  the murine  homolog.88The  importance  of E,,of  IL-5  was taken  from 
the results  of Shanafelt et  ais' working with  the murine homolog. These investigators  argue that as the A helix of murine  IL-5 can substitute 
for that of mGM-CSF, and that K,,  and E,,  (K12  and El,  in human IL-5)  are the only conserved helix A residues shared by the two  cytokines, 
that these two residues constitute a critical receptor binding  site. The solid lines indicate  the structurally  defined boundaries  of the helices. 
Empty circles above residues indicate surface orientation, filled circles indicate buried amino acids, and half-filled  circles indicate partially 
exposed  sites. Interestingly, although Asp,,  of 11-2 is not structurally equivalent to  GIu,,  of GM-CSF or Glu, of IL-4 (it  resides one turn higher 
up), the side chains fold such that the carboxylates are within 0.3  nm of one another and could easily interact with equivalent residues on 
their respective receptors. 
tial, hydrophobicity,  and shape to allow docking with its cell 
surface receptor complex. Signal transduction ensues upon 
ligand-induced receptor oligomerization and/or conforma- 
tional change. The goal of structure-function studies is to 
identify the nature of the structural core and the critical side 
chains responsible for receptor interaction. Long before any 
of the structural features of these proteins were known, in- 
vestigators applied a number of  mutagenesis methods to 
determine the sites of growth factor/growth factor receptor 
interaction. As attested to by the large number of available 
methods, no single method is optimal or entirely reliable. In 
the absence of physical data of receptor-ligand interaction, 
conclusions of contact points must be derived from mesh- 
ing data from multiple sources, and even then should still be 
considered as approximations. However, such predictions 
are often quite successful, as was recently shown for the 
interaction of GH and its receptop or the juxtaposition of 
two helices of GM-CSF based on an analysis of the binding 
epitopes of confirmation-dependent monoclonal antibodies 
(MoAbs).6‘ And  even when available, static physical data 
cannot determine the functional consequence of a specific 
receptor-ligand interaction. The physical details of a recep- 
tor-agonist interaction might closely resemble that of a re- 
ceptor-antagonist association. Functional correlations must 
be sought. 
The  most  conceptually  straightforward  approach  to 
structure-function  analysis is the synthetic peptide method. 
Alternately, recombinant DNA techniques can be used to 
generate a series of  truncated polypeptides that are then 
tested for biologic effects. This approach has occasionally 
been successful, as for the analysis of parathyroid hormone 
in which the amino terminal 34 residues may replace the 
intact 84 amino acid protein. Such truncated polypeptides 
then provide a vehicle for detailed study.@  However, in the 
case of the hematopoietic cytokines, such as murine IL-3 or 
human GM-CSF, only limited insights have been obtained 
from this  Because these methods do not allow 
investigators to differentiate between loss of activity due to 
the elimination of critical receptor-interactive residues or 
due to the loss of  sites required for maintenance of  the 
proper tertiary fold of the polypeptide, additional methods 
that either directly or indirectly assess the effects of deletion 
on structural integrity (physical methods such as crystallog- 
raphy  or  NMR  or  the  use  of  conformation-dependent 
MoAbs, eg, ref 65) must be included for conclusions from 
such studies to be considered rigorous. Internal deletion 
mutagenesis suffers from these same limitations. 
A method to determine the location or functional signifi- 
cance of putative helical regions is termed proline substitu- 
tion mutagenesis. For example, by introducing proline resi- 
dues to intentionally disrupt helical structure, Altmann et 
af6  determined that the second helix of murine GM-CSF 
was not necessary for full biologic activity. By  the same 
method Landgraf et aI6’@ systematically explored the struc- 
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Fig 4.  Helical wheel analysis  of helix D. A mukisequence align- 
ment of the fourth helices  of human GM-CSF, IL-4, IL-2.11-3, IL-5. 
and GH was conducted and is displayed in a helical wheel projec- 
tion. The line that bisects the helix indicates the hydrophobic/hy- 
drophilic interface. Simple inspection shows conservation of se- 
quence elements on the hydrophobic face of this helix. In contrast, 
other than a conserved basic residue corresponding to GM-CSF 
N,os, little or  no hydrophilic face conservation is noted. Sites at 
which GH interacts with its receptor are noted by a star (*). Only 
those fourth helix residues of GH that have structural counterparts 
in the short helix cytokines (F,,,6-Q,a,)  are shown. 
tural requirements for binding of the fourth alpha helix of 
human 1L-2 to its receptor. Because this method assumes 
that structural alterations are responsible for physiologic ef- 
fects, the same caveats noted for deletion mutagenesis need 
not be  applied, but it is still true that the mutation of a 
proline in a nonhelical region can disrupt critical structure. 
A variety of methods has been introduced to scan a poly- 
peptide for regions of functional significance. Like the dele- 
tion and truncation  methods, insertional mutagenesis (in 
which a  three- to four-residue  sequence is  randomly  in- 
serted into a polypeptide) and linker scanning studies (in 
which a synthetic oligonucleotide is used to produce a series 
of deletion/substitution mutants69)  have the virtue of being 
able to rapidly generate a relatively large number of mu- 
tants.  Unfortunately, these  methods also suffer from  the 
same potential to misinterpret loss of function mutants as 
indicative of sites of receptor interaction. 
In contrast, although single random site alanine substitu- 
tion mutagenesis is quite time consuming,70  it is the scan- 
ning technique most likely to  yield reliable results. Synthetic 
genes with interchangeable cassettes and polymerase chain 
reaction (PCR) mutagenesis are the most convenient meth- 
ods to generate the large numbers of  mutants required for 
comprehensive  analysis.  The resultant  mutants are ex- 
pressed and tested for biologic activity. The advantage of 
alanine substitution over that with other residues is the rela- 
tive tolerance shown by structurally critical residues. In con- 
trast, the loss of a specific side chain essential for receptor 
interaction (via hydrogen-bonding, ionic interaction, or hy- 
drophobic association)  is rarely tolerated.  Using this ap 
proach, Cunningham and Wellsa probed the interaction of 
GH  and its receptor and predicted its site of binding. Their 
results correlated very well with the sites of interaction de- 
termined by x-ray crystallographic analysis of a receptor-li- 
gand cocrystal?' 
Another scanning method applied successfully to the he- 
matopoietic growth factor field has been chimeric analysis. 
This approach is dependent on the species-specific biologic 
activity of homologs of a cytokine, such as that shown by 
GM-CSF,  IL-3, or IL-5,7'-73  or by cell surface molecules, 
such as the T-lymphocyte  marker CD4.74 Application  of 
this method reduces the risk that loss of function mutants 
will  result from gross structural alterations, as substituted 
regions of the molecule are capable of folding in similar 
ways (even ~25%  sequence identity can allow retention of 
tertiary structure7'). A conceptually similar strategy can be 
applied  using structurally related  molecules,  such as be- 
tween different members of the interferon or growth hor- 
mone/prolactin (PRL) fa mi lie^.^^^^^ Recently, we have used 
this technique to determine the sites of receptor interaction 
of GM-CSF7' and of  IL-3,72 and McKenzie  et a173 have 
mapped at least one site critical for IL-5/IL-5 receptor bind- 
ing. Although no ligand/receptor cocrystal structure is avail- 
able for comparison, conclusions derived from the biologic 
analysis of the GM-CSF and IL-3 interspecies hybrids are 
consistent with that of most substitution mutagenesis and 
MoAb mapping  studie~,6'~~**~'.~*  and the juxtaposition  of 
two putative receptor interaction sites of GM-CSF is consis- 
tent with the crystalline structure of the molecule.M 
Despite its advantages, chimeric analysis has at least two 
potential drawbacks. First, the biologic activity of a cyto- 
kine is likely caused by a combination  of species-specific 
and conserved residues. Inherent in its design, those critical 
receptor-interactive residues that are conserved among the 
homologs of a growth factor will not be identified. An exam- 
ple is Glu,,  of human GM-CSF, shown by site-specific mu- 
tagenesis to be  critical  for binding to the (3  chain of  the 
receptor.79 A second potential hazard  of chimeric growth 
factor  analysis  relates  to divergence among homologous 
proteins.  During this process, coupled changes (concerted 
evolution) may arise, which might be disrupted during the 
construction of an inter-species chimera. For example, the 
internal structure of  human GM-CSF is stabilized by the 
ionic and hydrogen bonding interactions of Ser,,,  Asp,, , 
and Lys107.30  In contrast, these residues have been replaced 
by the hydrophobic interaction of Metz6, Val,,,  and Helw, 
respectively, in the murine homolog. This type of concerted 
evolution cannot be predicted without detailed knowledge 
of the tertiary structure of a protein, a luxury rarely avail- 
able at the outset of structure-function studies. 
Once regions of potential receptor interaction have been 
identified by scanning methods most investigators test their 
predictions by site-directed mutagenesis. As noted, alanine 
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Fig 5.  Cylindrical plots oft e fourth helix of the growth factors shown in Fig 3 and 4. The SYN -.  representations are as described in the 
legend to Fig 3. In  addition, biologically permissible substitution sites are underlined  with an arrow and the residue involved in mutagenesis. 
The assignment of GH surface and buried residues is based on the figure from Cunningham and Wellsm because the three-dimensional 
coordinates were not available. Also note that the fourth helix is oriented downward in the up-up-down-down topology so that the helix 
actually extends above (and not below as on the figure) the others in a superimposition of the long-helix GH with the other short-helix 
cvtokines. 
substitution is often preferred. However, charged residues 
are often replaced with amino acids of opposite charge, or 
hydrophobic residues with  polar amino acids. Mutations 
are usually directed at predicted surface-oriented residues; 
not only are these likely to interact with receptor, but their 
mutation is least likely  to induce structural alterations. How- 
ever, in the absence of a tertiary structure, secondary struc- 
ture prediction programs must be used. Unfortunately, in 
the absence of  a homologous structure  for comparison, 
these programs are rarely more than 60% to 65% accurate. 
Thus, even with single site-directed mutants care must be 
exercised  in the interpretation of  results. For example, a 
W,,,K  mutation of human GM-CSF (tryptophan [W] 122 
to lysine [K]) resulted in substantial reduction of function; 
however, the native residue is partially buried such that alter- 
ation to lysine may lead to disruption of the local structure. 
This result could lead to the misassignment of W,22  as a 
receptor interactive site. Powerful structural methods are 
required for this type of analysis, but such examples serve to 
interject  caution  into  the  interpretation  of  seemingly 
“straightforward” mutagenesis studies. 
A fundamentally different and often complementary ap- 
proach to structure-function analysis depends on the map- 
ping of binding epitopes of neutralizing and nonneutraliz- 
ing  MoAbs of  a  growth  factor of  interest. However, a 
number of caveats need to be considered in interpreting the 
results of these studies. First, MoAbs may neutralize by in- 
teraction with a receptor binding site, by steric hindrance of 
the receptor binding site while bound to an adjacent, recep- 
tor-irrelevant site, or by MoAb binding-induced structural 
changes. The literature is replete with examples of the latter 
two circumstances,8%82  thus requiring care in the interpreta- 
tion of results. Consideration of steric hindrance becomes 
particularly important in that an intact MoAb is typically 
five times larger than a hematopoietic growth factor. The 
use of Fab fragments of MoAb can reduce some of these 
concerns. And  concerns  over  MoAb-induced structural 
changes can occasionally be overcome by demonstration of 
the simultaneous binding of other conformation-dependent 
(ie, tertiary structure-sensitive)  MoAbs (eg, ref 60). A second 
caveat concerns the use of neutralizing versus non-neutraliz- 
ing MoAbs. Because of steric considerations more rigorous 
information can often be obtained by mapping several non- 
neutralizing MoAbs than from neutralizing antibodies. Suc- 
cessful  MoAb  mapping  studies  have  been  reported  for 
GH,65  GM-CSF,61,78  IL-3,72  and IL-4.83  In all of these studies 
the sites of MoAb binding correlated well with independent 
measures of ligand-receptor interaction. 
HELICAL FACES OF GROWTH FACTORS INTERACT WITH 
TWO RECEPTOR  MOLECULES 
Most of the hematopoietic growth factor receptors consist 
of at least two s~bunits.~~,~~  In general, the two subunits 
differ in ligand binding affinity but the physiologically rele- 
vant receptor complex includes both subunits. And in those 
cases in which a single receptor polypeptide has been identi- 
fied (eg, GH), receptor-ligand stoichiometry is 2: l  .84 
It is clear that of the members of the cytokine family for 
which adequate data and a crystalline  structure are available 
the major sites of receptor-growth factor interaction lie on 
the surfaces of a-helices. Using the structure of a cocrystal of 
GH and its receptor, DeVos et a141 showed that two receptor 
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molecules simultaneously contact a single GH four-bundle 
helix. Of interest, the same region of each receptor molecule 
contacts two distinct sites of the GH  ligand. The largest area 
of contact is between one receptor molecule and a concave 
surface made up of the fourth helix, one exposed face of the 
first helix and a few residues of the AB connecting loop. The 
second receptor  molecule  in the complex  contacts addi- 
tional residues of the first helix and the free face of the third 
helix. 
Although a cocrystal of IL-2 and its a chain receptor (p55 
Tac) has been  structural data are not yet avail- 
able. However, from a number of structure-function studies 
the surfaces of the IL-2 helices also form the majority  of 
those sites deemed critical for receptor interaction. Using 
substitution mutagenesis,  Collins et als6 determined that 
Asp,,  and Phe,,,,  which reside within the first and fourth 
helices of human IL-2, are essential for interaction with the 
IL-2  receptor  ,l3  chain  (p70). Although  Phe,,,  is  located 
within  the structural core, the inactivation of IL-2 upon 
substitution of this residue points to the importance of the 
fourth helical region. Substitution mutagenesis studies by 
Zurawski and Zurawskis7 confirmed the importance of the 
surface of the first helix of murine IL-2 (specifically,  Asp,,) 
for interaction with the p70 receptor subunit, and also indi- 
cated  that a  short  stretch  of  residues just preceding  the 
fourth helix (in the structural model of Bazan3' and revised 
structure of McK~~,~)  interacts with the a chain of the IL-2 
receptor."  In addition, selective substitution mutagenesis at 
Gln,,,  (equivalent to human IL-2 Gln,,,)  resulted in IL-2 
antagonism by disrupting IL-2/IL-2R y chain intera~tion.'~ 
Of some interest, an analogous substitution of human IL-4 
(Tyr,,,)  also resulted  in an antagonist of this cytokine.gO 
Despite these findings, the precise role of the fourth helix in 
IL-2/IL-2 receptor interaction is unclear. Nearly all of the 
remaining surface residues of the fourth helix of the growth 
factor can be replaced with polar or charged residues with- 
out detrimental effects, as long as the helix remains struc- 
turally intact (see mutant I of ref 67). In contrast, proline 
mutants of this region reduce receptor binding. These re- 
sults suggest a critical structural role for the helix, but its 
importance in receptor recognition is less clear. 
For GM-CSF, chimeric analysis has indicated that sur- 
face residues of the first and third helices interact with the 
high-affinity GM-CSF re~eptor.~'  These findings were con- 
firmed by epitope mapping studies of neutralizing MoAbs 
of human GM-CSF.61  A more recent analysis using mixed- 
species receptors elegantly demonstrated that the p chain of 
the receptor interacts with the first GM-CSF alpha 
This finding was confirmed by careful kinetic analysis of a 
single site substitution mutant ofthis  region ofthe protein.79 
The fourth helix of GM-CSF also appears to interact with 
receptor, based on additional mapping studies of neutraliz- 
ing MoAb of GM-CSF,78  and the finding that substitution 
of the fourth helix of GM-CSF with the murine homolog 
reduces activity three-f~ld.~' 
A  UNIFIED  MODEL OF  HGF  STRUCTURE AND  FUNCTION 
As  the  above  examples  illustrate  the  hematopoietic 
growth factor family shares many structural features. Where 
data from x-ray crystallography or multidimensional NMR 
exist these cytokines are four-helix bundle proteins, the he- 
lices are oriented up-up-down-down, and are connected by 
loops that often contain additional elements of secondary 
structure (helices or p sheets). The alignment of the helices 
are also remarkably  similar. The core helix bundle of 63 
residues of IL-4 can be superimposed on the corresponding 
residues of GM-CSF with a root mean square (r.m.s.) devia- 
tion of only 0.14 nm.37  Extension of this analysis to M-CSF 
is also quite remarkable,  with an r.m.s.  deviation of only 
0.18 nm for the GM-CSF/M-CSF pairing and 0.17 nm for 
the M-CSF/GH ~airing.~'  The growth factors interact with 
at least two receptor molecules, either heterodimeric, as is 
the case for GM-CSF, IL-3, IL-5, or IL-2, or homodimeric, 
in the case of M-CSF and GH. And two opposing faces of 
the four-bundle helix interacts with each receptor subunit, 
usually a face composed of all or part of the fourth and first 
helices (as shown for GH,,'  IL-3,72  IL-5,73  1L-4,83  and IL-286) 
and one composed of all or part of the first and third helices 
(as shown for GM-CSF,71  IL-4,*, and GH41). At the amino 
acid level, there are further similarities. Alignment of the 
first helices of GM-CSF, IL-4, IL-5, and IL-2, and the pre- 
dicted first helix of  IL-3 shows a central, surface-oriented 
acidic residue (glutamic acid > aspartic acid) surrounded by 
surface-oriented hydrophobic amino acids (see Fig 3). This 
pattern fits nicely with ideas on protein-protein recognition 
which  suggest that hydrophobic groups provide  strength 
and hydrophilic groups provide specificity to the interac- 
ti~n.~,  Numerous mutagenesis studies of GM-CSF, IL-3, 
and IL-2 point to the importance of the acidic residue for 
receptor binding, specifically to the signal transducing sub- 
unit (pc and p70, respectively). Like the first helix, align- 
ment of the fourth helices of GM-CSF, IL-4, IL-2, IL-5, and 
GH, and the proposed fourth helix of IL-3 shows significant 
sequence similarity, first recognized by  Sanderson et a193 
(and Fig 4).  However, in contrast to conservation of surface- 
oriented residues in  the first helices, the majority  of se- 
quence shared by  the fourth helices of these cytokines is 
buried in the hydrophobic core of the proteins. This com- 
mon scaffold supports a highly polar and variable surface 
(Fig 5) shown to be critical for receptor interaction in at least 
four of the cytokines (GH,41  IL-3,72,94  IL-4,83,90  and IL-573). 
This surface has a greater area of receptor contact (at least 
for GH) or a higher affinity for receptor binding than that of 
the first helix and thus appears to account for receptor speci- 
ficity. 
EXPANSION TO  UNKNOWN STRUCTURES 
Presently, the rate at which new protein sequence is ob- 
tained from cDNA cloning far surpasses our accumulation 
of tertiary structures based on the physical methods of crys- 
tallography and resonance spectroscopy. Ultimately, a thor- 
ough understanding of the rules of protein folding will allow 
precise determination  of tertiary  structure  from primary 
amino acid sequence. Until then, molecular modeling of 
new structures will be inexact. Two approaches to model 
building have been applied within the growth factor field. 
Several groups have used computer-based algorithms to gen- 
erate de novo structural models. Commonly used programs 
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include those which predict sites of secondary ~tructure,~~'~' 
sites for possible  helix-helix intera~tion,~~  helix  pairings 
based on location and geometric preferences of interaction 
sites, and helix connectivity and geometric placement based 
on steric or disulfide constraints (see ref 99 and refs therein). 
Energy minimization is then used to finalize side chain and 
interconnecting loop geometry."  Such techniques can pro- 
vide models useful  for generating testable hypotheses for 
structure-function analysis. Unfortunately, such de novo 
model building based solely on the primary amino acid se- 
quence often  However, Boissel et al,,  recently 
used these principles and analogy to the distant homologs 
IL-4 and GH to build a tertiary structure model of human 
Epo. A series of short internal deletion mutants in the puta- 
tive helices and interhelical  loops of Epo were then prepared 
to test the model. For the most part, deletions within the 
projected helices or helix boundaries resulted in molecules 
that failed to be secreted from mammalian cells, implying a 
denatured structure. Most of the short deletions  predicted to 
lie between helices were tolerated both structurally (ie, they 
were processed properly and secreted)  and functionally (dis- 
played from 70%  to 80%  specific activity compared with the 
wild-type molecule). 
A second approach, homology model building, substi- 
tutes residues of a polypeptide of interest for those of a re- 
lated, known structure.Io3  For these exercises, the primary 
amino acid alignment becomes the prime determinant of 
model success. When dealing with interspecies homologs, 
this is straightforward. When building a model of a related 
growth factor, the task is more complex. There are often 
several pieces of information available to be used. First, a 
multi-sequence alignment of both the known and modeled 
proteins is often helpful. The alignment of multiple proteins 
may provide more information than the alignment of any 
pair of sequences as the increased sample size improves the 
chances that a permissible range of sequence variation will 
be observed. The principles of multiple sequence alignment 
are beyond the scope of this review, but are based on matri- 
ces  of  values designed to weigh  amino acid mismatches 
based  on their conservation within groups of structurally 
related proteins or protein modules (eg, ref  104). This topic 
has recently been  reviewed (see Methods  in Enzymology, 
Vol 183). Often, within a region of two or more molecules, 
several alignments  are plausible. In this case, additional data 
can often provide important insights. For example, highly 
conserved hydrophobic residues often indicate those posi- 
tions critical for core structural integrity.lo5  Their alignment 
with similarly conserved residues of like character in the 
sequence to be modeled is often helpful. Conserved hydro- 
philic residues often indicate sites essential for receptor in- 
teraction, particularly among homologs that display cross- 
species function.  Intron-exon  boundaries  often  overlap 
between functionally  and structurally related proteins, bely- 
ing their common evolutionary derivation, and often help- 
ing to align segments of the polypeptide structure (eg, ref 
106). Conserved disulfide linkages are of primary impor- 
tance for alignment amongst functionally or structurally re- 
lated proteins. And finally, and perhaps most useful, single 
residues shown to be critical for receptor interaction in one 
molecule are often conserved in the homolog to be mod- 
eled. For example, Gluzl,  present in the middle ofthe first (Y 
helix and shown to be critical for GM-CSF binding to the p 
chain of its receptor, aligns with Glu, of human IL-4 in a 
superimposition of the two crystalline structures. Together, 
these findings imply both that Glu, may be important for 
IL-4 function and that Glu,,  of IL-3, also present in the 
middle of the predicted first helix, provides a useful land- 
mark for alignment of the three structures, at least in the 
amino terminal region of the molecules. Once again, such 
extrapolations have their dangers because the functionally 
critical Asp,,  of IL-2 is not the structural equivalent of Glu,, 
of GM-CSF, but resides one turn further up the helix (how- 
ever, see legend to Fig 3). 
IMPLICATIONS FOR THE  BEGINNINGS  OF 
RATIONAL DRUG  DESIGN 
Recognizing the  sites at which growth factors interact 
with their receptors is a first important step in the rational 
manipulation of cytokines for therapeutic benefit. This re- 
view has focused on the sites at which several hematopoietic 
growth factors interact with their receptors. It should be 
apparent that many details are missing. Except for the case 
of  GH, structure-function studies have identified only a 
portion of those receptor interactive residues necessary for 
high-affinity binding. Using the GH/GH receptor interac- 
tion as a guide, several testable hypotheses of GM-CSF, IL- 
3, IL-5, IL-4, and IL-2 binding are suggested. However, it is 
clear that a detailed analysis of the type undertaken for GH 
can provide the necessary foundation for rationale cytokine 
manipulation. For example, by manipulating three residues 
previously shown to be critical for binding to the GH and 
PRL receptors, Cunningham and Wells'07  were able to engi- 
neer GH to preferentially stimulate the PRL receptor. Even 
greater progress has been reported for generation of GH 
antagonists.108  Despite these  accomplishments, however, 
large  polypeptides are required for biologic effects.  It  is 
hoped that mutational analysis  coupled with structure deter- 
mination might provide the opportunity to design confor- 
mationally constrained peptides or small organic molecules 
that mimic the local topology of critical receptor binding 
sites. At  that point, the approach of rational drug design 
holds the promise of delivering  important new therapeutics. 
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